Clinical Trials Logo

Stage I Renal Cell Cancer clinical trials

View clinical trials related to Stage I Renal Cell Cancer.

Filter by:

NCT ID: NCT06432036 Not yet recruiting - Clinical trials for Stage II Renal Cell Cancer

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Start date: January 1, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.

NCT ID: NCT04473781 Recruiting - Clinical trials for Stage II Renal Cell Cancer

Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

Start date: July 16, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable/unablatable). Brachytherapy, also known as internal radiation therapy, temporarily introduces a radiation source into or near the tumor to eradicate the tumor cells. Giving brachytherapy may potentially reduce the size of the kidney cancer mass that would otherwise not be amenable to surgical management and translate into lower risk of spread.

NCT ID: NCT02885649 Terminated - Clinical trials for Clear Cell Renal Cell Carcinoma

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Start date: December 5, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.

NCT ID: NCT02767921 Terminated - Clinical trials for Stage III Prostate Cancer

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Start date: August 2, 2016
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer. Recombinant EphB4-HSA fusion protein may block an enzyme needed for tumor cells to multiply and may also prevent the growth of new blood vessels that bring nutrients to the tumor. Giving recombinant EphB4-HSA fusion protein before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT02664883 Active, not recruiting - Healthy Subject Clinical Trials

Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

Start date: September 8, 2015
Phase:
Study type: Observational

This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients with kidney cancer in the laboratory may aid doctors in the early detection of cancer, monitor tumor response to therapy, detect the presence of occult spreading of disease, and identify early return of disease.

NCT ID: NCT02526511 Active, not recruiting - Clinical trials for Stage IV Renal Cell Cancer

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

Start date: April 15, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.

NCT ID: NCT02170389 Terminated - Clinical trials for Recurrent Renal Cell Carcinoma

Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer

Start date: October 14, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies vaccine therapy before surgery in treating patients with kidney cancer that has not spread to nearby lymph nodes or to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells when they are infused back into the body.

NCT ID: NCT01281488 Completed - Clinical trials for Recurrent Renal Cell Cancer

Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors

Start date: October 20, 2011
Phase: Phase 1
Study type: Interventional

RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery. PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding tumors in patients with kidney tumors

NCT ID: NCT01243359 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of sunitinib malate when given together with bevacizumab in treating patients with kidney cancer or advanced solid malignancies. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving sunitinib malate together with bevacizumab may kill more tumor cells.

NCT ID: NCT01158521 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Start date: June 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works when given before surgery in treating patients with kidney cancer.